Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer

References

• Boström J, Brown DG, Young RJ, Keserü GM. Expanding the medicinal chemistry synthetic toolbox. Nat Rev Drug Discov 2018;17:709–27.
   PubMed Web of Science ®Google Scholar
• Singh I, Rani R, Luxami V, Paul K. Synthesis of 5-(4-(1H-phenanthro[9,10-d]imidazol-2-yl)benzylidene)thiazolidine-2,4-dione as promising DNA and serum albumin-binding agents and evaluation of antitumor activity. Eur J Med Chem 2019;166:267–80.
   PubMed Web of Science ®Google Scholar
• El-dash Y, Elzayat E, Abdou AM, Hassan RA. Novel thienopyrimidine-aminothiazole hybrids: design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorganic Chemistry 2021;114:105137.
   PubMed Web of Science ®Google Scholar
• Caruso E, Malacarne MC, Marras E, et al. New BODIPYs for photodynamic therapy (PDT): synthesis and activity on human cancer cell lines. Bioorg Med Chem 2020;28:115737.
   PubMedGoogle Scholar
• Kassab AE, Gedawy EM, Hamed MIA, et al. Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:922–39.
   PubMed Web of Science ®Google Scholar
• El-Malah A, Mahmoud Z, Hamed Salem H, Abdou AM, et al. Design, ecofriendly synthesis, anticancer and antimicrobial screening of innovative Biginelli dihydropyrimidines using β-aroylpyruvates as synthons. Green Chem Lett Rev 2021;14:220–32.
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
   PubMed Web of Science ®Google Scholar
• Fikroh RA, Matsjeh S, Anwar C, et al. Synthesis and anticancer activity of (E)-2’-hydroxy-2-bromo-4,5-dimethoxychalcone against breast cancer (MCF-7) cell line. Molekul 2020;15:34–9.
   Google Scholar
• Rammohan A, Reddy JS, Sravya G, et al. Chalcone synthesis, properties and medicinal applications: a review. Environ Chem Lett 2020;18:433–58.
   Web of Science ®Google Scholar
• Sukumaran SD, Nasir SB, Tee JT, et al. Analogues of 2'-hydroxychalcone with modified C4-substituents as the inhibitors against human acetylcholinesterase. J Enzyme Inhib Med Chem 2021;36:130–7.
   PubMed Web of Science ®Google Scholar
• Emam SH, Sonousi A, Osman EO, et al. Design and synthesis of methoxyphenyl- and coumarin-based chalcone derivatives as anti-inflammatory agents by inhibition of NO production and down-regulation of NF-κB in LPS-induced RAW264.7 macrophage cells. Bioorg Chem 2021;107:104630.
   PubMed Web of Science ®Google Scholar
• Dan W, Dai J. Recent developments of chalcones as potential antibacterial agents in medicinal chemistry. Eur J Med Chem 2020;187:111980.
   PubMed Web of Science ®Google Scholar
• Sashidhara KV, Dodda RP, Sonkar R, Palnati GR, et al. Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents. Eur J Med Chem 2014;81:499–509.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Gong Z, et al. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding site. J Enzyme Inhib Med Chem 2020;35:139–44.
   PubMed Web of Science ®Google Scholar
• Ashour HF, Abou-zeid LA, El-Sayed MAA, Selim KB. 1,2,3-triazole-chalcone hybrids: synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. Eur J Med Chem 2020;189:112062.
   PubMed Web of Science ®Google Scholar
• Chouiter MI, Boulebd H, Pereira DM, et al. New chalcone-type compounds and 2-pyrazoline derivatives: synthesis and caspase-dependent anticancer activity. Future Med Chem 2020;12:493–509.
   PubMed Web of Science ®Google Scholar
• Bedos-Belval F, Rouch A, Vanucci-Bacqué C, Baltas M. Diaryl ether derivatives as anticancer agents – a review. Medchemcomm 2012;3:1356–72.
   Web of Science ®Google Scholar
• Pitsinos EN, Vidali VP, Couladouros EA. Diaryl ether formation in the synthesis of natural products. Eur J Org Chem 2011;2011:1207–22.
   Web of Science ®Google Scholar
• Yang SM, Huang ZN, Zhou ZS, et al. Structure-based design, structure-activity relationship analysis, and antitumor activity of diaryl ether derivatives. Arch Pharm Res 2015;38:1761–73.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Gong Z, et al. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem 2020;95:103565.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu JJ, Sun J, et al. Design, synthesis and biological evaluation of novel chalcone derivatives as antitubulin agents. Bioorg Med Chem 2012;20:3212–8.
   PubMed Web of Science ®Google Scholar
• Kurşun Aktar BS, ORUÇ-EMRE EE, Demirtas I, et al. Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents. Turkish J Chem 2018;42:482–92.
   Web of Science ®Google Scholar
• Dahlen K, Wallen EA, Grøtli M, Luthman K. Synthesis of 2,3,6,8-tetrasubstituted chromone scaffolds. J Org Chem 2006;71:6863–71.
   PubMed Web of Science ®Google Scholar
• Dyrager C, Friberg A, Dahlén K, et al. 2,6,8-Trisubstituted 3-hydroxychromone derivatives as fluorophores for live-cell imaging. Chemistry 2009;15:9417–23.
   PubMed Web of Science ®Google Scholar
• Dias TA, Duarte CL, Lima CF, et al. Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin. Eur J Med Chem 2013;65:500–10.
   PubMed Web of Science ®Google Scholar
• Jain UK, Bhatia RK, Rao AR, et al. Design and development of halogenated chalcone derivatives as potential anticancer agents. Trop J Pharm Res 2014;13:73–80.
   Web of Science ®Google Scholar
• Bilginer S, Gul HI, Erdal FS, et al. New halogenated chalcones with cytotoxic and carbonic anhydrase inhibitory properties: 6-(3-Halogenated phenyl-2-propen-1-oyl)-2(3H)-benzoxazolones. Arch Pharm 2020;353:1900384–8.
   Web of Science ®Google Scholar
• Schmitt F, Draut H, Biersack B, Schobert R. Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity. Bioorg Med Chem Lett 2016;26:5168–71.
   PubMed Web of Science ®Google Scholar
• Saavedra E, Del Rosario H, Brouard I, et al. ′6'-Benzyloxy-4-bromo-2'-hydroxychalcone is cytotoxic against human leukaemia cells and induces caspase-8- and reactive oxygen species-dependent apoptosis. Chem Biol Interact 2019;298:137–45.
   PubMed Web of Science ®Google Scholar
• dos Santos MB, Bertholin Anselmo D, de Oliveira JG, et al. Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. J Enzyme Inhib Med Chem 2019;34:1093–9.
   PubMed Web of Science ®Google Scholar
• Pontes O, Costa M, Santos F, et al. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment. Eur J Med Chem 2018;157:101–14.
   PubMed Web of Science ®Google Scholar
• Reddy Kotha R, G Kulkarni R, Garige AK, et al. Synthesis and cytotoxic activity of new chalcones and their flavonol derivatives. Med Chem 2017;7:353–60.
   Google Scholar
• Fayed EA, Eldin RRE, Mehany A, et al. Isatin-Schiff’s base and chalcone hybrids as chemically apoptotic inducers and EGFR inhibitors; design, synthesis, anti-proliferative activities and in silico evaluation. J Mol Struct 2021;1234:130159.
   Web of Science ®Google Scholar
• Abdelhafez OM, Ahmed EY, Abdel Latif NA, et al. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds. Bioorg Med Chem 2019;27:1308–19.
   PubMed Web of Science ®Google Scholar
• Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006;5:824–8.
   PubMed Web of Science ®Google Scholar
• Sharma R, Kumar R, Kodwani R, et al. A review on mechanisms of anti tumor activity of chalcones. Anticancer Agents Med Chem 2015;16:200–11.
   PubMed Web of Science ®Google Scholar
• Matiadis D, Sagnou M. Pyrazoline hybrids as promising anticancer agents: an up-to-date overview. Int J Mol Sci 2020;21:1–41.
   Web of Science ®Google Scholar
• Zheng X, Ding J, Chen J, et al. The coupling of arylboronic acids with nitroarenes catalyzed by rhodium. Org Lett 2011;13:1726–9.
   PubMedGoogle Scholar
• Kumar P, Tripathi L. A new class of anticonvulsants possessing 6 Hz psychomotor seizure test activity: 2-(1H-benzotriazol-1-yl)-N'-[substituted] acetohydrazides. Med Chem 2012;8:337–48.
   PubMed Web of Science ®Google Scholar
• Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827–33.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Esmat A, Al-Abd AM, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life 2013;65:716–29.
   PubMed Web of Science ®Google Scholar
• Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. 2005;44:16475–90.
   Google Scholar
• RCSB PDB. https://www.rcsb.org/structure/2BAL.
   Google Scholar
• Pambudi W, Haryadi W, Matsjeh S, Indarto I. The effectiveness of hydroxychalcone synthesis by using NaOH and Naoh + Zro2 montmorillonite catalyst through conventional and microwave assisted organic synthesis (Maos) method. J Phys Conf Ser 2019;1155:12074.
   Google Scholar
• Sivasankerreddy L, Nagamani B, Rajkumar T, et al. Novel diazenyl containing phenyl styryl ketone derivatives as antimicrobial agents. Anti-Infective Agents 2019;17:28–38.
   PubMedGoogle Scholar
• Simmler C, Lankin DC, Nikolić D, et al. Isolation and structural characterization of dihydrobenzofuran congeners of licochalcone A. Fitoterapia 2017;121:6–15.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Han F, Lee IS. Microbial transformation of licochalcones. Molecules 2019;25:60.
   PubMed Web of Science ®Google Scholar
• Hassan SY. Synthesis and biological activity of some new pyrazoline and pyrimidine derivatives. J Braz Chem Soc 2011;22:1286–98.
   Web of Science ®Google Scholar
• Karabacak M, Altintop MD, Çiftçi HI, et al. Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents. Molecules 2015;20:19066–84.
   PubMed Web of Science ®Google Scholar
• Suma AAT, Wahyuningsih TD, Pranowo D. Synthesis and antibacterial activities of n-phenylpyrazolines from veratraldehyde. Mater Sci Forum 2017;901:124–32.
   Google Scholar
• Jiang Y, Cai NN, Zhao XX, et al. Decreased abundance of GDNF mRNA transcript in the immature Sertoli cells of cattle in response to protein kinase inhibitor staurosporine. Anim Reprod Sci 2020;214:1–9.
   Web of Science ®Google Scholar
• Xue LY, Chiu SM, Oleinick NL. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. Exp Cell Res 2003;283:135–45.
   PubMed Web of Science ®Google Scholar
• Alsamman K, El-Masry OS. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62. Oncol Rep 2018;40:2157–62.
   PubMed Web of Science ®Google Scholar
• Goksen US, Sarigul S, Bultinck P, et al. Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity. Chirality 2019;31:21–33.
   PubMed Web of Science ®Google Scholar
• Wei L, Wu J, Li G, Shi N. Cis-enone resorcylic acid lactones (RALs) as irreversible protein kinase inhibitors. Curr Drug Metab 2012;18:1186–98.
   Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar
• Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 2012;55:743–53.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 2014;94:329–54.
   PubMed Web of Science ®Google Scholar
• He L, He T, Farrar S, et al. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 2017;44:532–53.
   PubMed Web of Science ®Google Scholar
• Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010;3:23–34.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li S, Cao Y, et al. Oxidative stress and carbonyl lesions in ulcerative colitis and associated colorectal cancer. Oxid Med Cell Longev 2016;2016:9875298.
   PubMed Web of Science ®Google Scholar
• Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 2000;55:29–35.
   PubMed Web of Science ®Google Scholar
• Strathmann J, Klimo K, Sauer SW, et al. Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism. FASEB J 2010;24:2938–50.
   PubMed Web of Science ®Google Scholar
• Takac P, Kello M, Vilkova M, et al. Antiproliferative effect of acridine chalcone is mediated by induction of oxidative stress. Biomolecules 2020;10:345.
   PubMed Web of Science ®Google Scholar
• Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1–15.
   PubMed Web of Science ®Google Scholar
• Tsai PW, Shiah SG, Lin MT, et al. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem 2003;278:5750–9.
   PubMed Web of Science ®Google Scholar
• Suarez-Cuervo C, Merrell MA, Watson L, et al. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004;21:525–33.
   PubMed Web of Science ®Google Scholar
• Parekh P, Motiwale L, Naik N, Rao KVK. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 2011;63:167–73.
   PubMedGoogle Scholar
• Soni S, Anand P, Padwad YS. MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression. J Exp Clin Cancer Res 2019;38:121.
   PubMed Web of Science ®Google Scholar